Targeted Therapy in Pancreatic Cancer: New Insights and Challenges

What Is Pancreatic Cancer?

Cancer that starts as a proliferation of cells in the pancreas is known as pancreatic cancer. Beneath the lower portion of the stomach is the pancreas. It produces hormones to help control blood sugar levels and enzymes to aid in food digestion. The most prevalent kind of pancreatic cancer is called pancreatic ductal adenocarcinoma. Digestion enzymes are expelled from the pancreas through ducts lined with cells of this type. When there is the best possibility of a cure, pancreatic cancer is rarely discovered in its early stages. It frequently does not show symptoms until it has moved to other organs, which explains why.

What Is Targeted Therapy?

Cancer treatment, known as targeted therapy, targets specific characteristics of cancer cells while causing minimal damage to healthy cells. Targeted medicines obstruct the actions that turn cancerous cells from normal ones. Blocking these pathways will inhibit the proliferation of cancer cells. In most cases, targeted medicines do not affect healthy cells. In comparison to other treatments, they typically have fewer adverse effects. Each treatment's targeted therapy side effects are unique. Each patient will also react to treatment differently. Supportive care could be useful.

What Targeted Therapies Are Available for Pancreatic Cancer?

There are several targeted therapies approved by the Food and Drug Administration (FDA) for certain groups of pancreatic cancer patients, which are as follows:

1. Erlotinib.

2. Sunitinib.

3. Everolimus.

4. Larotrectinib.

5. Entrectinib.

6. Olaparib.

Patients must undergo testing for several of these treatments to determine whether they have the mutations (changes) that the medicines are targeting. This testing consists of:

Testing blood or saliva for genetic alterations a patient was born with or received from a parent is known as inherited mutation testing. Molecular profiling, often known as tumor biomarker testing, involves examining tumor tissue for mutations.

How Are Targeted Therapies Incorporated in Pancreatic Cancer?

1. BRAF Inhibitor:

• A tiny percentage of pancreatic tumors have BRAF gene mutations, especially the BRAFV600E mutant. Cancer and aberrant cell proliferation may result from this gene mutation.

• If a BRAFV600E mutation is discovered in a patient's unresectable pancreatic cancer, therapeutic options include trametinib (Mekinist) and dabrafenib given in combination.

• These medications are taken twice a day in pill form.

• Chills, fever, night sweats, fatigue, skin rash, nausea, vomiting, diarrhea, abdominal discomfort, edema in the hands or feet, joint aches, decreased appetite, muscle aches, and headaches are typical adverse effects of these medications.

2. NTRK Inhibitors:

• There is a tiny percentage of pancreatic tumours with altered NTRK genes. Cancer and aberrant cell proliferation can occasionally result from these gene alterations.

• In the event that an NTRK gene fusion mutation is discovered in unresectable pancreatic cancer, therapy options include larotrectinib and entrectinib, which are administered as a single drug (alone). These medications are given once or twice a day as pills.

• These medications frequently cause dizziness, exhaustion, nausea, vomiting, constipation, weight gain, and diarrhea as adverse effects. Confusion, cardiac issues, and abnormal liver tests are less frequent but more dangerous side effects.

3. RET Inhibitor:

• The RET gene is altered in a tiny percentage of pancreatic tumors. Cancer and aberrant cell proliferation can occasionally result from these gene alterations.

• If the RET gene fusion mutation is identified in unresectable pancreatic cancer, selercatinib may be a viable therapy option.

• This medication is used twice a day in capsule form.

• Atypical LFT (liver function test) results, low platelets and white blood cells, dry mouth, constipation, diarrhea, elevated blood pressure, fatigue, and skin rash are typical adverse effects of this medication.

4. KRAS Inhibitor:

• KRAS gene alterations, more especially the KRAS G12C mutation, are present in a tiny percentage of pancreatic tumors. A mutation in this gene may cause cancer and aberrant cell proliferation.

• If the KRAS G12C mutation is discovered in pancreatic cancer that is incurable, patients may be treated with sotorasib or adagrasib as a single agent (alone). Usually, these medications are only taken into consideration if previous treatments have not improved the pancreatic cancer's response or have made it worse.

• These medications are given orally, once or twice a day.

• These medications frequently cause nausea, vomiting, diarrhoea, aches in the muscles, decreased appetite, and abnormal results on liver and kidney tests. Changes in laboratory results, such as liver function tests (LFTs), white blood cells, red blood cells, and electrolytes (sodium and potassium), are less frequent but more dangerous adverse effects that may occur.

5. EGFR Inhibitor:

• The medication erlotinib targets the EGFR protein in cancer cells, which often promotes cell growth. Gemcitabine, a chemotherapy medicine, may be used in addition to this medication for patients with advanced pancreatic cancer. This combination might be more advantageous to some persons than to others.

• This medication is given once daily as a tablet.

• Erlotinib's side effects can include weariness, diarrhea, lack of appetite, and a rash on the face and neck that resembles acne. Less frequent but more dangerous side effects include severe bleeding or blood clotting issues; holes (perforations) growing in the stomach or intestines; and major damage to the liver, kidneys, or lungs.

6. PARP Inhibitor:

• A few BRCA genes (BRCA1 or BRCA2) are altered in the cells of a limited percentage of pancreatic tumors. Cancer may occasionally result from modifications to one of these genes.

• One class of medication known as a PARP inhibitor is olaparib (Lynparza). Normally, PARP enzymes are part of a process that aids in the mending of damaged DNA within cells. A mutation in one of the BRCA genes can stop the other DNA repair mechanism that these genes are normally involved in. This medication makes it extremely difficult for tumor cells with mutant BRCA genes to repair damaged DNA, which frequently results in their death. It does this by also blocking the PARP pathway.

• Patients with germline BRCA1 or BRCA2 mutations who have unresectable pancreatic cancer may be eligible for olaparib as a therapy. It is used as a maintenance treatment, particularly if platinum-based chemotherapy (such as oxaliplatin or cisplatin) has been administered for at least four months and the pancreatic cancer has not progressed.

• Although its potential to extend survival has not yet been established, this medication has been demonstrated to help reduce or delay the growth of some advanced pancreatic tumors.

• This medication is given orally as pills, usually twice daily.

• This medication frequently causes low red blood cell counts (anemia), low white blood cell counts (with an increased risk of infection), stomach ache, muscular and joint pain, nausea, vomiting, diarrhea or constipation, exhaustion, feeling lightheaded, loss of appetite, taste changes, and low red blood cell counts. Lung inflammation and the emergence of certain blood malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), are less frequent but more dangerous adverse effects.

What Are Targeted Therapy in Clinical Trials?

• There are still further targeted treatments for pancreatic cancer being researched in labs or in clinical trials.

• Clinical trials are research projects that evaluate novel experimental therapies. The aim is to develop more effective pancreatic cancer therapies.

• Trials are the only way to advance the treatment of the condition and give patients the chance to receive a potential investigational medicine or treatment.

• Patients participating in clinical trials typically receive experimental targeted therapies in addition to more common forms of care, such as chemotherapy, radiation, or surgery.

Conclusion:

Targeted therapy is a type of cancer treatment that selectively targets cancer cells while sparing healthy cells as much damage as possible. The processes that differentiate healthy cells from malignant ones are blocked by targeted medications. The growth of cancer cells will be impeded by blocking these mechanisms. Targeted medications typically do not harm healthy cells. Generally speaking, they have less side effects than other medicines. The side effects of targeted therapy are specific to each treatment. Also, every patient will respond to treatment in a unique way. Helping others may be beneficial.